FDA advisers will review Talon's leukemia drug Marqibo

02/5/2012 | American City Business Journals

The FDA asked an advisory committee to assess Marqibo, Talon Therapeutics' drug candidate for Philadelphia chromosome-negative acute lymphoblastic leukemia, on March 21. Marqibo is a capsule form of approved cancer treatment vincristine.

View Full Article in:

American City Business Journals

Published in Briefs: